Most patients with epidermal growth factor receptor-mutant advanced non-small-cell lung cancer eventually experience disease progression on initial treatments, according to findings presented by Shun Lu at the European Society for Medical Oncology Congress 2026 and published on October 25, 2026, in the New England Journal of Medicine, ascopost.com reported.
MET dysregulation drives this resistance in 34% of cases.
The international, phase 3 SAFFRON trial screened 1,746 patients and randomly assigned 338 participants whose disease progressed on osimertinib. Patients received either an investigational combination of oral osimertinib at 80 mg once daily and savolitinib at 300 mg twice daily, or intravenous platinum-pemetrexed chemotherapy, as detailed by NEJM.
In the full analysis set, median progression-free survival reached 7.6 months with the combination therapy compared to 5.4 months for chemotherapy, translating to a 45% reduction in the risk of disease progression or death, ascopost.com reported. Median overall survival reached 17.8 months versus 12.9 months, representing a 32% reduction in the risk of death. Twelve-month overall survival rates were 70% versus 53%. The overall survival data were 53% mature at the time of analysis.

“Osimertinib plus savolitinib establishes a new global standard of care for patients with EGFR-mutant advanced non–small cell lung cancer with MET overexpression and/or amplification after progression on osimertinib,” said Shun Lu, MD, PhD, of the Department of Medical Oncology at Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, as reported by ascopost.com.
“SAFFRON establishes the clinical value of an all-oral biomarker-directed treatment approach targeting both EGFR and MET following progression on osimertinib, reinforcing osimertinib as a backbone treatment across lines of therapy,” he said.
“Progression-free survival by blinded independent central review in the MET-overexpressed and MET-amplified analysis sets was generally consistent with the full analysis set,” he said.